To evaluate safety and tolerability of tucatinib used in combination with palbociclib and
letrozole, and to confirm that current RP2D of tucatinib and FDA approved dosing of
palbociclib remain the same in the triplet combination
Endocrine therapies are commonly used to treat hormone-related cancers such as breast and prostate cancers. However, resistance to these therapies is a persistent challenge. The objective of this proposal is to understand dynamic changes of ER /AR-bound enhancers during cancer progression. The knowledge gained will increase our ability to assess therapeutic responsiveness in breast and prostate cancers.
To compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not, defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC.
To demonstrate the superiority of radiation therapy localization using specialized light-based surface imaging without the use of permanent tattoos for daily alignment for radiation treatment in women with biopsy-proven ductal carcinoma in-situ (DCIS) or invasive breast cancer who will be receiving radiation therapy postoperatively when compared to the use of temporary skin markings and to historical data of patients aligned with permanent tattoos alone.